Company Overview

Atomo is a medical device company headquartered in Sydney, Australia, and is establishing an in-house assembly and packing facility in South Africa, and has a commercial office in the UK.

Established in 2010, the Company’s primary focus is the expansion of global sales and continued development of its proprietary rapid test device technologies that simplify testing processes and reduce errors compared to more complex conventional bloodbased rapid diagnostic testing (RDT) kits.

Atomo is a public company incorporated in Australia. It successfully raised A$30 million through an initial public offering with quotation of its shares commencing on ASX on 16 April 2020 under ASX Code AT1.